留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

老年肿瘤免疫检查点抑制剂临床治疗进展

唐辉 周建凤 白春梅

唐辉, 周建凤, 白春梅. 老年肿瘤免疫检查点抑制剂临床治疗进展[J]. 协和医学杂志, 2020, 11(4): 459-464. doi: 10.3969/j.issn.1674-9081.2020.04.018
引用本文: 唐辉, 周建凤, 白春梅. 老年肿瘤免疫检查点抑制剂临床治疗进展[J]. 协和医学杂志, 2020, 11(4): 459-464. doi: 10.3969/j.issn.1674-9081.2020.04.018
Hui TANG, Jian-feng ZHOU, Chun-mei BAI. Clinical Progress of Immune Checkpoint Inhibitors in the Elderly[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(4): 459-464. doi: 10.3969/j.issn.1674-9081.2020.04.018
Citation: Hui TANG, Jian-feng ZHOU, Chun-mei BAI. Clinical Progress of Immune Checkpoint Inhibitors in the Elderly[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(4): 459-464. doi: 10.3969/j.issn.1674-9081.2020.04.018

老年肿瘤免疫检查点抑制剂临床治疗进展

doi: 10.3969/j.issn.1674-9081.2020.04.018
基金项目: 

中国医学科学院医学与健康科技创新工程 2016-12M-1-001

详细信息
    通讯作者:

    周建凤  电话:010-69158764, E-mail:ZhouJF@pumch.cn

  • 中图分类号: R730.51

Clinical Progress of Immune Checkpoint Inhibitors in the Elderly

More Information
    Corresponding author: ZHOU Jian-feng  Tel: 86-10-69158764, E-mail:ZhouJF@pumch.cn
  • 摘要: 免疫检查点抑制剂(immune checkpoint inhibitors, ICIs)是当今肿瘤治疗领域的革命性突破, 改变了多种肿瘤治疗模式。老年人占肿瘤现患人数及死亡人数的绝大部分, 老年肿瘤患者存在免疫衰老、自身免疫性疾病及感染性疾病发生率高、肿瘤突变负荷与年轻患者存在差异等均可能影响ICIs疗效。在大部分ICIs临床试验中, 老年肿瘤患者在受试人群中未能占据应有比例, 亚组分析及荟萃分析结果提示年龄对疗效及免疫相关不良反应的发生影响较小。临床医生可参考相关试验数据, 在体能状态较好的老年肿瘤患者中使用ICIs, 以积累更多的真实世界数据。
    利益冲突  无
  • [1] Kennedy LC, Bhatia S, Thompson JA, et al. Preexisting Autoimmune Disease:Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors[J]. J Natl Compr Canc Netw, 2019, 17:750-757. doi:  10.6004/jnccn.2019.7310
    [2] Cuzzubbo S, Javeri F, Tissier M, et al. Neurological adverse events associated with immune checkpoint inhibitors:Review of the literature[J]. Eur J Cancer, 2017, 73:1-8. doi:  10.1016/j.ejca.2016.12.001
    [3] SEER Cancer Statistics Review(CSR)1975-2017[EB/OL]. https.//seer.cancer.gov/csr/1975_2017/.
    [4] Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019[J]. CA Cancer J Clin, 2019, 69:363-385. doi:  10.3322/caac.21565
    [5] Repetto L, Audisio RA. Elderly patients have become the leading drug consumers:it's high time to properly evaluate new drugs within the real targeted population[J]. J Clin Oncol, 2006, 24:e62-e63. doi:  10.1200/JCO.2006.09.3039
    [6] Singh H, Beaver JA, Kim G, et al. Enrollment of older adults on oncology trials:An FDA perspective[J]. J Geriatr Oncol, 2017, 8:149-150. doi:  10.1016/j.jgo.2016.11.001
    [7] Daste A, Domblides C, Gross-Goupil M, et al. Immune checkpoint inhibitors and elderly people:A review[J]. Eur J Cancer, 2017, 82:155-166. doi:  10.1016/j.ejca.2017.05.044
    [8] Kirschner K, Chandra T, Kiselev V, et al. Proliferation Drives Aging-Related Functional Decline in a Subpopulation of the Hematopoietic Stem Cell Compartment[J]. Cell Rep, 2017, 19:1503-1511. doi:  10.1016/j.celrep.2017.04.074
    [9] Della Bella S, Bierti L, Presicce P, et al. Peripheral blood dendritic cells and monocytes are differently regulated in the elderly[J]. Clin Immunol, 2007, 122:220-228. doi:  10.1016/j.clim.2006.09.012
    [10] Pence BD, Yarbro JR. Aging impairs mitochondrial respira-tory capacity in classical monocytes[J]. Exp Gerontol, 2018, 108:112-117. doi:  10.1016/j.exger.2018.04.008
    [11] van Duin D, Allore HG, Mohanty S, et al. Prevaccine determination of the expression of costimulatory B7 molecules in activated monocytes predicts influenza vaccine responses in young and older adults[J]. J Infect Dis, 2007, 195:1590-1597. doi:  10.1086/516788
    [12] Bottazzi B, Riboli E, Mantovani A. Aging, inflammation and cancer[J]. Semin Immunol, 2018, 40:74-82. doi:  10.1016/j.smim.2018.10.011
    [13] Agrawal A, Gupta S. Impact of aging on dendritic cell functions in humans[J]. Ageing Res Rev, 2011, 10:336-345. doi:  10.1016/j.arr.2010.06.004
    [14] Cura Daball P, Ventura Ferreira MS, Ammann S, et al. CD57 identifies T cells with functional senescence before terminal differentiation and relative telomere shortening in patients with activated PI3 kinase delta syndrome[J]. Immunol Cell Biol, 2018, 96:1060-1071. doi:  10.1111/imcb.12169
    [15] Zelle-Rieser C, Thangavadivel S, Biedermann R, et al. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site[J]. J Hematol Oncol, 2016, 9:116. doi:  10.1186/s13045-016-0345-3
    [16] Moreira A, Gross S, Kirchberger MC, et al. Senescence markers:Predictive for response to checkpoint inhibitors[J]. Int J Cancer, 2019, 144:1147-1150. doi:  10.1002/ijc.31763
    [17] Aspinall R, Carroll J, Jiang S. Age-related changes in the absolute number of CD95 positive cells in T cell subsets in the blood[J]. Exp Gerontol, 1998, 33:581-591. doi:  10.1016/S0531-5565(98)00035-7
    [18] Cicin-Sain L, Smyk-Pearson S, Currier N, et al. Loss of naive T cells and repertoire constriction predict poor response to vaccination in old primates[J]. J Immunol, 2010, 184:6739-6745. doi:  10.4049/jimmunol.0904193
    [19] Effros RB, Boucher N, Porter V, et al. Decline in CD28+ T cells in centenarians and in long-term T cell cultures:a possible cause for both in vivo and in vitro immunosenescence[J]. Exp Gerontol, 1994, 29:601-609. doi:  10.1016/0531-5565(94)90073-6
    [20] Bulati M, Caruso C, Colonna-Romano G. From lymphopoiesis to plasma cells differentiation, the age-related modifications of B cell compartment are influenced by "inflamm-ageing"[J]. Ageing Res Rev, 2017, 36:125-136. doi:  10.1016/j.arr.2017.04.001
    [21] Pawelec G. Does patient age influence anti-cancer imm-unity?[J]. Semin Immunopathol, 2019, 41:125-131. doi:  10.1007/s00281-018-0697-6
    [22] Jagger A, Shimojima Y, Goronzy JJ, et al. Regulatory T cells and the immune aging process:a mini-review[J]. Gerontology, 2014, 60:130-137. doi:  10.1159/000355303
    [23] Flores RR, Clauson CL, Cho J, et al. Expansion of myeloid-derived suppressor cells with aging in the bone marrow of mice through a NF-κB-dependent mechanism[J]. Aging Cell, 2017, 16:480-487. doi:  10.1111/acel.12571
    [24] Rosenkranz D, Weyer S, Tolosa E, et al. Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration[J]. J Neuroimmunol, 2007, 188:117-127. doi:  10.1016/j.jneuroim.2007.05.011
    [25] Coppé JP, Desprez PY, Krtolica A, et al. The senescence-associated secretory phenotype:the dark side of tumor suppression[J]. Annu Rev Pathol, 2010, 5:99-118. doi:  10.1146/annurev-pathol-121808-102144
    [26] Watad A, Bragazzi NL, Adawi M, et al. Autoimmunity in the Elderly:Insights from Basic Science and Clinics-A Mini-Review[J]. Gerontology, 2017, 63:515-523. doi:  10.1159/000478012
    [27] Khan SA, Pruitt SL, Xuan L, et al. Prevalence of Autoimmune Disease Among Patients With Lung Cancer:Implications for Immunotherapy Treatment Options[J]. JAMA Oncol, 2016, 2:1507-1508. doi:  10.1001/jamaoncol.2016.2238
    [28] Toi Y, Sugawara S, Sugisaka J, et al. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer[J]. JAMA Oncol, 2019, 5:376-383. doi:  10.1001/jamaoncol.2018.5860
    [29] Yoneshima Y, Tanaka K, Shiraishi Y, et al. Safety and Efficacy of PD-1 Inhibitors in Non-Small Cell Lung Cancer Patients Positive for Antinuclear Antibodies[J]. Lung Cancer, 2019, 130:5-9. doi:  10.1016/j.lungcan.2019.01.014
    [30] de Moel EC, Rozeman EA, Kapiteijn EH, et al. Autoantibody development under treatment with immune-checkpoint inhibitors[J]. Cancer Immunol Res, 2019, 7:6-11. doi:  10.1158/2326-6066.CIR-18-0245
    [31] Scott SC, Pennell NA. Early Use of Systemic Corticosteroids in Patients with Advanced NSCLC Treated with Nivolumab[J]. J Thorac Oncol, 2018, 13:1771-1775. doi:  10.1016/j.jtho.2018.06.004
    [32] Arbour KC, Mezquita L, Long N, et al. Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer[J]. J Clin Oncol, 2018, 36:2872-2878. doi:  10.1200/JCO.2018.79.0006
    [33] Fucà G, Galli G, Poggi M, et al. Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors[J]. ESMO Open, 2019, 4:e000457. doi:  10.1136/esmoopen-2018-000457
    [34] Ricciuti B, Dahlberg SE, Adeni A, et al. Immune Check-point Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications[J]. J Clin Oncol, 2019, 37:1927-1934. doi:  10.1200/JCO.19.00189
    [35] Francino MP. Antibiotics and the Human Gut Microbiome:Dysbioses and Accumulation of Resistances[J]. Front Microbiol, 2016, 6:1543.
    [36] Pinato DJ, Gramenitskaya D, Altmann DM, et al. Antibiotic therapy and outcome from immune-checkpoint inhibitors[J]. J Immunother Cancer, 2019, 7:287. doi:  10.1186/s40425-019-0775-x
    [37] Huang XZ, Gao P, Song YX, et al. Antibiotic Use and the Efficacy of Immune Checkpoint Inhibitors in Cancer Patients:A Pooled Analysis of 2740 Cancer Patients[J]. Oncoimmunology, 2019, 8:e1665973.
    [38] Pinato DJ, Howlett S, Ottaviani D, et al. Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer[J]. JAMA Oncol, 2019, 5:1774-1778. doi:  10.1001/jamaoncol.2019.2785
    [39] Podolskiy DI, Lobanov AV, Kryukov GV, et al. Analysis of cancer genomes reveals basic features of human aging and its role in cancer development[J]. Nat Commun, 2016, 7:12157. doi:  10.1038/ncomms12157
    [40] Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100, 000 human cancer genomes reveals the landscape of tumor mutational burden[J]. Genome Med, 2017, 9:34. doi:  10.1186/s13073-017-0424-2
    [41] Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J]. Science, 2015, 348:124-128. doi:  10.1126/science.aaa1348
    [42] Sileni VC, Pigozzo J, Ascierto PA, et al. Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme[J]. J Exp Clin Cancer Res, 2014, 33:30. doi:  10.1186/1756-9966-33-30
    [43] Leroy V, Gerard E, Dutriaux C, et al. Adverse events need for hospitalization and systemic immunosuppression in very elderly patients (over 80 years) treated with ipilimumab for metastatic melanoma[J]. Cancer Immunol Immunother, 2019, 68:545-551. doi:  10.1007/s00262-019-02298-9
    [44] Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation[J]. N Engl J Med, 2015, 372:320-330. doi:  10.1056/NEJMoa1412082
    [45] Kugel CH, Douglass SM, Webster MR, et al. Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations[J]. Clin Cancer Res, 2018, 24:5347-5356. doi:  10.1158/1078-0432.CCR-18-1116
    [46] Nosrati A, Tsai KK, Goldinger SM, et al. Evaluation of clinicopathological factors in PD-1 response:derivation and validation of a prediction scale for response to PD-1 monotherapy[J]. Br J Cancer, 2017, 116:1141-1147. doi:  10.1038/bjc.2017.70
    [47] Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2015, 373:1627-1639. doi:  10.1056/NEJMoa1507643
    [48] Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2015, 373:123-135. doi:  10.1056/NEJMoa1504627
    [49] Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2018, 379:2040-2051. doi:  10.1056/NEJMoa1810865
    [50] Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2018, 378:2078-2092. doi:  10.1056/NEJMoa1801005
    [51] Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):a randomised controlled trial[J]. Lancet, 2016, 387:1540-1550. doi:  10.1016/S0140-6736(15)01281-7
    [52] Nishijima TF, Muss HB, Shachar SS, et al. Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients:A systematic review and meta-analysis[J]. Cancer Treat Rev, 2016, 45:30-37. doi:  10.1016/j.ctrv.2016.02.006
    [53] Elias R, Giobbie-Hurder A, McCleary NJ, et al. Efficacy of PD-1& PD-L1 inhibitors in older adults:a meta-analysis[J]. J Immunother Cancer, 2018, 6:26. doi:  10.1186/s40425-018-0336-8
    [54] Wu Q, Wang Q, Tang X, et al. Correlation between patients' age and cancer immunotherapy efficacy[J]. Oncoimmunology, 2019, 8:e1568810. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=10.1080/2162402X.2019.1568810
    [55] Herin H, Aspeslagh S, Castanon E, et al. Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours[J]. Eur J Cancer, 2018, 95:68-74. doi:  10.1016/j.ejca.2018.03.002
    [56] Dudnik E, Moskovitz M, Daher S, et al. Effectiveness and safety of nivolumab in advanced non-small cell lung cancer:The real-life data[J]. Lung Cancer, 2018, 126:217-223. doi:  10.1016/j.lungcan.2017.11.015
    [57] Muchnik E, Loh KP, Strawderman M, et al. Immune Checkpoint Inhibitors in Real-World Treatment of Older Adults with Non-Small Cell Lung Cancer[J]. J Am Geriatr Soc, 2019, 67:905-912. doi:  10.1111/jgs.15750
    [58] Lichtenstein MRL, Nipp RD, Muzikansky A, et al. Impact of Age on Outcomes with Immunotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC)[J]. J Thorac Oncol, 2019, 14:547-552. doi:  10.1016/j.jtho.2018.11.011
    [59] Sattar J, Kartolo A, Hopman WM, et al. The Efficacy and Toxicity of Immune Checkpoint Inhibitors in A Real-World Older Patient Population[J]. J Geriatr Oncol, 2019, 10:411-414. doi:  10.1016/j.jgo.2018.07.015
    [60] de Velasco G, Je Y, Bossé D, et al. Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients[J]. Cancer Immunol Res, 2017, 5:312-318. doi:  10.1158/2326-6066.CIR-16-0237
    [61] Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade[J]. N Engl J Med, 2018, 378:158-168. doi:  10.1056/NEJMra1703481
    [62] Leins H, Mulaw M, Eiwen K, et al. Aged murine hematopoietic stem cells drive aging-associated immune remodeling[J]. Blood, 2018, 132:565-576. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=b2843c420e2791a3ccf06d34c11a7f93
    [63] Pawelec G. Immunosenescence and cancer[J]. Biogerontology, 2017, 18:717-721. doi:  10.1007/s10522-017-9682-z
  • 加载中
计量
  • 文章访问数:  157
  • HTML全文浏览量:  15
  • PDF下载量:  81
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-11-22
  • 刊出日期:  2020-07-30

目录

    /

    返回文章
    返回